These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22179721)

  • 41. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
    Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
    J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
    Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subversion of the Bcl-2 life/death switch in cancer development and therapy.
    Adams JM; Huang DC; Strasser A; Willis S; Chen L; Wei A; van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S
    Cold Spring Harb Symp Quant Biol; 2005; 70():469-77. PubMed ID: 16869785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway.
    Yu T; Chen C; Sun Y; Sun H; Li TH; Meng J; Shi X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):286-91. PubMed ID: 26116776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
    Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
    Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.
    Boiani M; Daniel C; Liu X; Hogarty MD; Marnett LJ
    J Biol Chem; 2013 Mar; 288(10):6980-90. PubMed ID: 23341456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK.
    Guo X; Yin S; Dong Y; Fan L; Ye M; Lu J; Hu H
    Mol Carcinog; 2013 Nov; 52(11):879-89. PubMed ID: 22711297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
    PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
    Konopleva M; Contractor R; Tsao T; Samudio I; Ruvolo PP; Kitada S; Deng X; Zhai D; Shi YX; Sneed T; Verhaegen M; Soengas M; Ruvolo VR; McQueen T; Schober WD; Watt JC; Jiffar T; Ling X; Marini FC; Harris D; Dietrich M; Estrov Z; McCubrey J; May WS; Reed JC; Andreeff M
    Cancer Cell; 2006 Nov; 10(5):375-88. PubMed ID: 17097560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A.
    Cippà PE; Kamarashev J; Chen J; Kraus AK; Segerer S; Feldmeyer L; Fehr T
    Apoptosis; 2013 Mar; 18(3):315-23. PubMed ID: 23208368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bcl-2 modulation to activate apoptosis in prostate cancer.
    Bray K; Chen HY; Karp CM; May M; Ganesan S; Karantza-Wadsworth V; DiPaola RS; White E
    Mol Cancer Res; 2009 Sep; 7(9):1487-96. PubMed ID: 19737977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.
    Singh A; Jayanthan A; Farran A; Elwi AN; Kim SW; Farran P; Narendran A
    Leuk Res; 2011 Dec; 35(12):1649-57. PubMed ID: 21798596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.
    Zall H; Weber A; Besch R; Zantl N; Häcker G
    Mol Cancer; 2010 Jun; 9():164. PubMed ID: 20576107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
    Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC
    Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
    Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
    Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.
    Hiraki M; Suzuki Y; Alam M; Hinohara K; Hasegawa M; Jin C; Kharbanda S; Kufe D
    Sci Rep; 2016 May; 6():26643. PubMed ID: 27217294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.